Advancing synthetic therapies for the treatment of restless legs syndrome. (2nd November 2019)

• Record Type: Journal Article
• Authors: de Biase, Stefano; Pellitteri, Gaia; Gigli, Gian Luigi; Valente, Mariarosaria
• Is Part Of: Expert opinion on pharmacotherapy. Volume 20:Number 16(2019)
• Page Start: 1971
• Page End: 1980
• Publication Date: 2019-11-02
• Subjects: Augmentation -- α2δ calcium channel ligand -- dopamine -- investigational drugs -- iron -- MAO-B inhibitors -- oxycodone-naloxone -- restless legs syndrome; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2019.1654997
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Restless Legs Syndrome/Willis-Ekbom disease (RLS/WED) is a common sensory-motor neurological disorder that impairs nocturnal rest causing decreased alertness, depressed mood, reduced job performance and poor quality of life. In patients affected by moderate to severe RLS/WED, a pharmacological treatment is mandatory. Areas covered : The present review is based on an extensive Internet and PubMed search from 1996 to 2019. It is focused on drugs currently used and under development (phase III and beyond) for the treatment of RLS/WED. Expert opinion : The drugs currently available for the treatment of the disease do not always allow for obtaining the optimal control of symptoms, in particular in the long-term treatment. Although initially effective, long-term dopaminergic treatment tends to wane over time and augmentation can occur. Updated international guidelines now recommend α2δ calcium channel ligand medications as the initial drug of choice. Oxycodone-naloxone demonstrated a significant and sustained treatment effect for patients with severe RLS/WED insufficiently controlled with previous treatments. Head-to-head trials of different drugs, as well as more studies on nondopaminergic agents and combination therapy, are greatly needed. Monoamine oxidase B inhibitors could be good candidates for the initial treatment of RLS/WED, sparing stronger dopaminergic agents for later stages of the disease.